FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84051
News■ Unclear/unknown
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 2026
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A diagnostics pipeline launch is product news without disclosed commercial scale.
Diagnostics launch, unproven commercial traction
CATALYST TO WATCH
ASHG conference adoption signals
MAIN RISK
Private company, no tradable impact
FULL DISPATCH
New pipeline offers the potential to analyze up to 23 disease-associated repeat expansion loci in a single, low-cost run PROVIDENCE, R.I., Oct. 15, 2026 /PRNewswire/ -- Nabsys 2.0, LLC ("Nabsys") today announced the release of RepX™, a repeat expansion analysis pipeline available through...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
→CORRELATIONshares Healthcare
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
Cyrano Therapeutics Announces Presentation of Positive Phase 2 FLAVOR Data Demonstrating Statistically Significant Improvement in Smell Function with CYR-064 in Patients with Post-Viral Smell Loss2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
CTY IPO News - City Therapeutics prices upsized IPO at $18, the midpoint of the range2026-10-16 12:47 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.